...
首页> 外文期刊>Journal of Human Reproductive Sciences >Can intracytoplasmic Morphologically Selected Spermatozoa Injection be Used as First Choice of Treatment for Severe Male Factor Infertility Patients?
【24h】

Can intracytoplasmic Morphologically Selected Spermatozoa Injection be Used as First Choice of Treatment for Severe Male Factor Infertility Patients?

机译:胞质形态选择精子注射液可作为重度男性不育症患者的首选治疗方法吗?

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Aim: This study was carried out to assess the outcome of the intracytoplasmic morphologically selected sperm injection (IMSI) technique compared with the previous failed intracytoplasmic sperm injection (ICSI) attempts in oligoasthenoteratozoospermia (OAT)/severe OAT (SOAT)/teratozoospermia patients. Setting: Institution-based, in vitro fertilization center. Study Design: It was a nonrandomized prospective study including 57 couples who had previous one or two ICSI failures (failure due to no implantation as embryos were transferred in these cycles and had no pregnancy) due to male factor. There was no case of total fertilization failure. IMSI was carried out in these couples and the results were compared with their previously failed ICSI attempts. Materials and Methods: Real-time selection of sperms was done using IMSI as it allows the assessment of fine nuclear morphology and vacuoles in the sperm head at a high magnification (>6000×) with differential interference contrast optics. Therefore, IMSI was applied in couples having OAT, SOAT or teratozoospermia as male factor and the results were compared with their previous failed ICSI attempts. Statistical analysis was carried out using GraphPad Prism. Results and Conclusion: Data analysis demonstrated significant difference in the fertilization rate between IMSI and previous ICSI attempts of these patients (30.0% vs. 52.0%; P < 0.05). The embryo quality, implantation and pregnancy rates with IMSI were also significantly higher than those of their previous ICSI cycles (32% vs. 56.4%; 30.2% vs. 68.5%; 0.0% vs. 62.4%; P < 0.05). Our conclusion is that the IMSI procedure improved embryo development and the clinical outcomes in the same infertile couples with male infertility and poor embryo development over their previous ICSI attempts and can be taken up as the treatment of choice in cases of severe male factor infertility.
机译:目的:本研究旨在评估胞浆内形态选择的精子注射技术(IMSI)与先前在少脂非小动脉精子症(OAT)/重度OAT(SOAT)/畸形精子症患者中进行的胞浆内精子注射(ICSI)失败的尝试。地点:基于机构的体外受精中心。研究设计:这是一项非随机的前瞻性研究,其中包括57对因男性因素而曾经历过一两次ICSI失败(由于在这些周期中转移了胚胎并且没有怀孕而没有植入而失败)的夫妇。没有完全失败的案例。在这些夫妇中进行了IMSI,并将结果与​​他们先前失败的ICSI尝试进行了比较。材料和方法:使用IMSI进行精子的实时选择,因为它可以使用差分干涉对比光学系统以高放大倍数(> 6000x)评估精子头部的精细核形态和液泡。因此,IMSI被应用于以OAT,SOAT或畸形性精子症为男性因素的夫妇,并将结果与​​他们先前失败的ICSI尝试进行了比较。使用GraphPad Prism进行统计分析。结果与结论:数据分析表明,这些患者的IMSI与以前的ICSI尝试之间的受精率存在显着差异(30.0%对52.0%; P <0.05)。 IMSI的胚胎质量,着床率和妊娠率也显着高于之前的ICSI周期(32%比56.4%; 30.2%比68.5%; 0.0%比62.4%; P <0.05)。我们的结论是,与之前的ICSI尝试相比,IMSI程序改善了具有男性不育和胚胎发育不良的同一对不育夫妇的胚胎发育和临床结局,可作为严重男性因子不育病例的治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号